Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis

Part of Nephritis

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Focal Segmental Glomerulosclerosis

13 trials tracked for Focal Segmental Glomerulosclerosis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 110 citations.

13Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 11 Other / NA 1
  1. Phase 3 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Completed · 110 cited
  2. Phase 2 Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Completed
  3. Phase 2 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Completed
  4. Phase 2 Podocyte Retinoids Completed
  5. Phase 2 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Completed
  6. Phase 2 A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS Completed
Show 7 more trials
  1. Phase 2 A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) Completed
  2. Phase 2 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Completed
  3. Phase 2 Permeability Factor in Focal Segmental Glomerulosclerosis Completed
  4. Phase 2 Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis Completed
  5. Phase 2 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Completed
  6. Phase 2 A Study of CCX140-B in Subjects With FSGS Completed
  7. N/A Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Focal Segmental Glomerulosclerosis: what the trials found

Sparsentan demonstrated a statistically significant higher percentage of participants achieving the FSGS Partial Remission Endpoint (FPRE) compared to the control group (42.0% vs 26.0%, p=0.0094) 1. However, there was no significant difference in the slope of estimated Glomerular Filtration Rate (eGFR) between groups, either overall or following the initial acute effect of treatment 1.

Adalimumab showed a reduction in Urine Protein Creatinine Ratio (UPCR) by 11.60 2. However, in a separate trial, no participants achieved a reduction in proteinuria of >50% with stable GFR at 6 months 11.

Recent results — preliminary, needs further review

  • Bardoxolone methyl capsules showed a statistically significant improvement in eGFR at week 12 (p=<0.0001) 5.
  • RE-021 (Sparsentan) was associated with varying percentages of patients achieving the FSGS Partial Remission Endpoint (FPRE) across different cohorts 6.
  • Cyclophosphamide showed a statistically significant reduction in proteinuria in recurrent FSGS following renal transplant with plasma exchange (p=<0.0001) 12.
  • D-Galactose was associated with a significant difference in the Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) (p=0.009) 13.

For the clinician treating this condition

  • Sparsentan is associated with a significantly higher rate of FSGS Partial Remission (FPRE) compared to standard care, while maintaining stable eGFR slopes 1.
  • Adalimumab has shown evidence of reducing UPCR, though results regarding concurrent stabilization of GFR are not consistently positive across trials [2, 11].

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rheumatology Cohort
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Frontiers Apr 24, 2026
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Nephrology
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…
Frontiers Apr 1, 2026
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Nephrology Phase III
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar.
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
CT.gov Mar 30, 2026
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Nephrology Phase II
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
CT.gov Mar 27, 2026
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Nephrology Phase II
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.
CT.gov Mar 27, 2026

Questions about Focal Segmental Glomerulosclerosis

Are Frexalimab, Brivekimig, and Rilzabrutinib being tested together to treat Focal Segmental Glomerulosclerosis?

No, Frexalimab, Brivekimig, and Rilzabrutinib are not being tested together. A current Phase 2 study tests these drugs individually against a placebo to see which one reduces proteinuria in FSGS.

Full answer →
Is obinutuzumab an option for FSGS patients who did not respond to rituximab?

Yes, obinutuzumab has shown promise in case reports and small studies for FSGS patients who did not respond to rituximab, but larger trials are needed.

Full answer →